Recruiting

β2-Agonists

Sponsor:

University of British Columbia

Code:

NCT07037511

Conditions

Asthma

Healthy

Effect of Drug

Eligibility Criteria

Sex: All

Age: 18 - 55

Healthy Volunteers: Accepted

Interventions

Salbutamol

Placebo

Study Details

Brief summary:

β2-Agonists, commonly used to treat asthma, have also been used by athletes to enhance performance, leading to their ban by the International Olympic Committee in 1972. Research has shown non-asthmatics receive no benefit from these drugs at therapeutic dosages; however, many elite athletes still use them, and asthmatic athletes often win more Olympic medals. In some non-asthmatics, β2-agonists may improve breathing limitations during high intensity exercise, which may improve performance. Therefore, we aim to examine if there is a select group of non-asthmatic individuals who experience breathing limitations that may receive benefit from β2-agonists.

Conditions

Asthma

Healthy

Effect of Drug

Study ID

NCT07037511

Start date

Oct 30, 2025

Status verified date

Jun, 2025

Completion date

Dec 31, 2030

Anticipated

Primary completion date

Dec 31, 2029

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 55

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Aerobic capacity (V̇O2max) greater than 120% predicted
  • Body mass index (BMI) > 18 and < 30 kg/m2
  • Ability to read and understand English
  • Currently training and/or competing in endurance sports (i.e. running or cycling)

Exclusion Criteria:

  • Smoking history or currently smoking. Currently smoking is defined as regular use of cigarettes or cannabis at any point in the past year. History of smoking is defined as smoking more than 1 pack year for cigarettes or the equivalent in cannabis use measured as puffs per day / 200 (number of puffs in a pack of cigarettes).
  • Use of cannabis within the past 30 days or has a smoking history of at least 1 pack year.
  • Use of vaping devices or e-cigarettes in the past 30 days, or has used them more than 10 times in their lifetime.
  • History or current symptoms of cardiopulmonary disease (excluding controlled asthma)
  • Contraindications to exercise testing defined as anything that would prevent exercise under proper and safe conditions (e.g., a problem with the heart or lungs, muscle)
  • Neuromuscular or musculoskeletal condition

Study Design

Enrollment

64 participants

Anticipated

Allocation

Randomized

Intervention Model

Crossover

Primary purpose

Basic Science

Interventions and Outcome Measures

Arms

active comparator: Salbutamol inhaler

Participants will take four inhalations of salbutamol, with 60 seconds between each inhalation, totaling a therapeutic dose of 400µg of salbutamol prior to performing an incremental cardiopulmonary exercise test.

placebo comparator: Placebo inhaler

Participants will take four inhalations of placebo, with 60 seconds between each inhalation, prior to performing an incremental cardiopulmonary exercise test.

Interventions

Salbutamol

Meter-dose inhaler of salbutamol performed using large-volume spacer

Placebo

Meter-dose inhaler of placebo performed using large-volume spacer

Primary outcome measure

  • Difference in time to exhaustion following salbutamol inhalation compared to placebo inhalation. [ Time Frame: Up to 2 weeks ]
  • Sex differences in time to exhaustion following salbutamol inhalation [ Time Frame: Up to 2 weeks ]

Central Contacts and Locations

Central contacts

Satvir S Dhillon, MSc

604-806-8835satvir.dhillon@hli.ubc.ca

Jordan A Guenette, PhD

604-806-8835jordan.guenette@hli.ubc.ca

Locations

St. Paul's Hospital

Recruiting

Vancouver, British Columbia, Canada, V6Z1Y6

Contacts

Alanna Hind, MSc

604-806-8835alanna.hind@hli.ubc.ca

Principal Investigator:

Jordan A Guenette, PhD

More Information

Sponsor

University of British Columbia

Last update posted

Mar 13, 2026

Last verified

Jun, 2025

Keywords

  • Exercise Physiology
  • Expiratory Flow Limitation
  • Non-Asthmatics
  • Beta2-Agonists

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of British Columbia on 2026-03-13.